Summary by Futu AI
Yichang East Sunlight Changjiang Pharmaceutical Co., Ltd. (the “Company”) and Guangdong Sunlight Pharmaceutical Co., Ltd. (the “Prospective Bidder”) issued a joint announcement on 8 April 2024 updating the progress of the Company regarding potential bidders who may absorb the merger through the exchange method. Pursuant to Rule 3.7 of the Hong Kong Securities and Exchange Code of Companies, potential bidders have been granted two waivers to the executors: one exemption from compulsory comprehensive contractual liability, and the other from the obligation to pay cash or provide cash options in respect of a possible merger. At present, the potential Contractors have not yet proposed a clear plan for the merger, the structure, terms and other details of the merger remain uncertain, and there is uncertainty as to whether the merger will take place. The Company will update monthly and consolidate possible progress in accordance with the Acquisition Code until a final decision is made. Shareholders and potential investors are reminded to exercise caution when trading shares.